UNIVERSITY OF CEBU-BANILAD

COLLEGE OF NURSING

DRUG STUDY

Patient: B.R Age: 77 years old Hospital No. 293998 Room No. 711

Impression/Diagnosis: Acute parenchymal bleed, left middle cerebellar area sepsis to secondary to diabetic foot Attending Physician(s): Dr. Romero, Chela Marie
Tanato

Allergy to: None

Generic/ Brand Name & Dosage Timing & Duration Indication/Pharmacodynamics of Drug Side Effects/ Adverse Nursing Responsibilities Patient Teaching
Classification Reaction/ Contraindication
(5%) (20%) (Nursing Process Approach) (20 %)
(5％) (10%)
(40%)

Generic Name: Drug form & Dosage Indications: Side Effects: Assessment  Do not abruptly
Ordered: discontinue medication.
Amlodipine Management of hypertension, coronary artery Frequent (greater than 5%):  Assess baseline
 Compliance with therapy
10 mg/tab disease (chronic stable angina, vasospastic Peripheral edema, headache, renal/hepatic function tests,
regimen is essential to
[Prinzmetal’s or variant] flushing. B/P, apical pulse.
control hypertension.
(Kizior & Hodgson, 2021) Occasional (5%–1%): Interventions  Avoid tasks that require
Dizziness, palpitations, nausea, alertness, motor skills until
Brand Name: unusual fatigue or weakness  Assess B/P (if systolic B/P response to drug is
Timing: Pharmacodynamics (asthenia). is less than 90 mm Hg, established.
withhold medication,  Do not ingest grapefruit
O.D. Inhibits calcium movement across cardiac and Rare (less than 1%): Chest contact physician).
vascular smooth muscle cell membranes pain, bradycardia, orthostatic products
 Assess for peripheral
during depolarization. hypotension. (Kizior & Hodgson, 2021)
edema behind medial
Classification Name: Therapeutic Effect: Dilates coronary arteries,
Adverse Effects: malleolus (sacral area in
peripheral arteries/arterioles. Decreases total
PHARMACOTHERAPEUTIC: peripheral vascular resistance and B/P by bedridden pts).
Overdose may produce  Assess skin for flushing.
Calcium channel blocker Duration: vasodilation.
excessive peripheral Question for headache,
(dihydropyridine). (Kizior & Hodgson, 2021)
vasodilation, marked asthenia.
CLINICAL: Antihypertensive, hypotension with reflex
antianginal. tachycardia, syncope. (Kizior & Hodgson, 2021)
Pharmacokinetics Contraindication
Route Onset Peak Duration Hypersensitivity to amlodipine
P.O. Unknown 6–12 hr 24 hr or its components

Slowly absorbed from GI tract. Protein (Kizior & Hodgson, 2021)

Other drug forms:
binding: 95%–98%. Metabolized in liver.
Excreted primarily in urine. Not removed by
 Tablets: 2.5 mg, 5 mg, 10 mg hemodialysis. Half-life: 30–50 hrs (increased
in elderly, pts with hepatic cirrhosis)

___Sheila K. Maceda, RN, MAN__ _______CLAIRE MAURICE G. JUANERO_____

Printed Name and Signature Printed Name and Signature
Clinical Instructor Student

UNIVERSITY OF CEBU-BANILAD
 COLLEGE OF NURSING

DRUG STUDY

Patient: B.R Age: 77 years old Hospital No. 293998 Room No. 711

Impression/Diagnosis: Acute parenchymal bleed, left middle cerebellar area sepsis to secondary to diabetic foot Attending Physician(s): Dr. Romero, Chela Marie
Tanato

Allergy to: None

Generic/ Brand Name & Dosage Timing & Duration Indication/Pharmacodynamics of Drug Side Effects/ Adverse Nursing Responsibilities Patient Teaching
Classification Reaction/ Contraindication
(5%) (20%) (Nursing Process Approach) (20 %)
(5％) (10%)
(40%)

Generic Name: Drug form & Dosage Indications: Side Effects: Assessment  Emphasize that
Ordered: atorvastatin is an adjunct to
Atorvastatin Primary prevention of cardiovascular disease Common: Atorvastatin is  Obtain baseline —not a substitute for—a
40 mg/tab in high-risk pts. Reduces risk of stroke and generally well tolerated. Side cholesterol, triglycerides, low-cholesterol diet.
heart attack A Canadian trade name Non- effects are usually mild and LFT.
 Tell patient to take drug at
Crushable Drug High Alert drug atorvastatin transient.  Obtain dietary history. the same time each day to
Brand Name: 95 in pts with type 2 diabetes with or without
Frequent (16%): Headache. maintain its effects.
evidence of heart disease. Reduces risk of Interventions
stroke in pts with or without evidence of heart  Instruct patient to take a
Occasional (5%–2%): Myalgia,  Monitor for headache.
Timing: disease with multiple risk factors other than missed dose as soon as
rash, pruritus, allergy.  Assess for rash, pruritus,
diabetes. possible. If it’s almost time
O.D. malaise.
Rare (less than 2%–1%): for his next dose, he should
(Kizior & Hodgson, 2021) Flatulence, dyspepsia,  Monitor cholesterol,
Classification Name: skip the missed dose. Tell
triglyceride lab values for
depression. him not to double the dose.
PHARMACOTHERAPEUTIC: therapeutic response.
 Instruct patient to consult
Hydroxymethylglutaryl CoA Adverse Effects:  Monitor LFTs, CPK.
Pharmacodynamics prescriber before taking
(HMG-CoA) reductase Duration: Potential for cataracts, OTC niacin because of
inhibitor. Inhibits HMG-CoA reductase, the enzyme (Kizior & Hodgson, 2021)
photosensitivity, myalgia, increased risk of
that catalyzes the early step in cholesterol
CLINICAL: rhabdomyolysis. rhabdomyolysis.
synthesis. Results in an increase of expression
Antihyperlipidemic.  Advise patient to notify
in LDL receptors on hepatocyte membranes Contraindication
and a stimulation of LDL catabolism. prescriber immediately if
Active hepatic disease, he develops unexplained
Therapeutic Effect: Decreases LDL and
breastfeeding, hypersensitivity muscle pain, tenderness, or
VLDL, plasma triglyceride levels; increases
to atorvastatin or its weakness, especially if
HDL concentration.
components, pregnancy, accompanied by fatigue or
(Kizior & Hodgson, 2021) unexplained persistent rise in fever.
Other drug forms: serum transaminase level.  Reinforce the benefits of
Tablets: 10 mg, 20 mg, 40 mg, therapy, and urge patient to
(Kizior & Hodgson, 2021)
80 mg comply if possible.
 Advise patient with
 Pharmacokinetics diabetes to monitor blood
glucose levels closely.
Poorly absorbed from GI tract.
Protein binding: greater than 98%.
Metabolized in liver. Primarily excreted in
feces (biliary).
Half-life: 14 hrs

___Sheila K. Maceda, RN, MAN__ _______CLAIRE MAURICE G. JUANERO_____

Printed Name and Signature Printed Name and Signature
Clinical Instructor Student